Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease - Concepedia

Concepedia

Publication | Open Access

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

DOI Full Paper Access

36

Citations

31

References

2019

Year

Mafalda Ramos, V. Foos, Anastasia Ustyugova, N. Hau, Pranav Gandhi, Mark Lamotte

Diabetes Therapy

Abstract

Boehringer Ingelheim International GmbH.

References

	Year	Citations

Page 1